.png)
CANCER
GENETIC CANCER RISK
Female Breast
High Risk
Pancreatic
High Risk
Prostate
High Risk
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Female Breast
To age 50
Up to 9%
2.1%
To age 80
17%-52%
10.7%
Pancreatic
To age 80
5%
1.1%
Prostate
To age 80
26%-44%
10.5%
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Female Breast
Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.
Individualized
NA
Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling
When genetic risk is identified, but not before age 21
Every 6 to 12 months
Mammography
Age 40, or modified to a younger age based on the family history of breast cancer
Annually
Consider breast MRI with contrast
30 to 35 years, or modified to a younger age based on the family history of breast cancer
Annually
Consider additional risk-reduction strategies.
Individualized
NA
Pancreatic
For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.
Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family
Annually
Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.
Individualized
Individualized
Incorporating information about increased risk due to gene mutation, start risk and benefit discussion about offering baseline digital rectal examination (DRE) and Prostate Specific Antigen (PSA).
Age 40
Individualized, consider annually
Prostate
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., PARP-inhibitors).
NA
NA
